Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year (FY) 2022 Concepts
- Notice of Special Interest (NOSI)—Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research
- Notice of Special Interest (NOSI)—Dirty Mouse Models of Human Immunity
- Notice of Special Interest (NOSI)—Immune Responses to Arthropod Feeding on Vertebrate Hosts
- Notice of Special Interest (NOSI)—Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes
- Notice of Special Interest (NOSI)—Understanding the Immune Functions of DEAD/H-box Helicases
FY 2023 Concepts
- SUNBEAM-Analysis and Bioinformatics Center
- Limited Competition To Continue the Controlling and Preventing Asthma Progression and Severity in Kids
- Development of Microbiome-Related Approaches for Diagnosis/Mitigation/Treatment of Radiation Injuries
Notice of Special Interest (NOSI)—Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research
For the published notice of special interest, check the July 29, 2021 Guide notice, Notice of Special Interest (NOSI): Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research.
Notice of Special Interest (NOSI)—Dirty Mouse Models of Human Immunity
For the published notice of special interest, check the October 20, 2021 Guide notice, Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity.
Notice of Special Interest (NOSI)—Immune Responses to Arthropod Feeding on Vertebrate Hosts
For the published notice of special interest, check the July 29, 2021 Guide notice, Notice of Special Interest (NOSI): Immune Responses to Arthropod Feeding on Vertebrate Hosts.
Notice of Special Interest (NOSI)—Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes
For the published notice of special interest, check the October 19, 2021 Guide notice, Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes.
Notice of Special Interest (NOSI)—Understanding the Immune Functions of DEAD/H-box Helicases
For the published notice of special interest, check the July 22, 2021 Guide notice, Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases.
SUNBEAM-Analysis and Bioinformatics Center
For the published request for applications, check the September 20, 2021 Guide announcement, SUNBEAM – Analysis and Bioinformatics Center (ABC) (UM1, Clinical Trial Not Allowed).
Limited Competition To Continue the Controlling and Preventing Asthma Progression and Severity in Kids
Request for Applications—proposed FY 2023 initiative
Contact: Lisa M. Wheatley
Objective: The PARK (Preventing Asthma in high Risk Kids) trial is designed to evaluate whether anti-IgE (omalizumab) can prevent asthma in two- to three-year old children at high risk due to aeroallergen sensitization and recurrent wheeze. The grant application scored in the 5th percentile, and the trial is mentioned in numerous publications as being an important step to advance our understanding of the pathogenesis of asthma. In this trial, the children are treated with omalizumab or placebo for two years and then followed for an additional two years. Asthma will be diagnosed in the second post-treatment year.
Description: This initiative will support the two-year follow up of the enrolled participants to completion and analysis of this clinical trial.
Development of Microbiome-Related Approaches for Diagnosis/Mitigation/Treatment of Radiation Injuries
For the published request for applications, check the September 20, 2021 Guide announcement, Development of Microbiome-Related Approaches for Diagnosis/Mitigation/Treatment of Radiation Injuries (U01, Clinical Trial Not Allowed).